Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Volume 7, 2013 - Issue 5
Submit an article Journal homepage
180
Views
11
CrossRef citations to date
0
Altmetric
Review

Advancements in pancreatic neuroendocrine tumors

Miral R Sadaria Department of Surgery, University of Colorado Anschutz Medical Campus, Division of GI, Tumor and Endocrine Surgery, Academic Office One, 12631 East 17th Avenue, C311, Aurora, CO 80045, USA; Department of Surgery, University of Colorado Anschutz Medical Campus, Division of GI, Tumor and Endocrine Surgery, Academic Office One, 12631 East 17th Avenue, C311, Aurora, CO 80045, USA
,
Ralph H Hruban Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Department of Pathology, Weinberg 2242, 401 North Broadway, Baltimore, MD, 21231, USA; Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins University School of Medicine, Department of Pathology, Weinberg 2242, 401 North Broadway, Baltimore, MD, 21231, USA
&
Barish H Edil Department of Surgery, University of Colorado Anschutz Medical Campus, Division of GI, Tumor and Endocrine Surgery, Academic Office One, 12631 East 17th Avenue, C311, Aurora, CO 80045, USA. [email protected]; Department of Surgery, University of Colorado Anschutz Medical Campus, Division of GI, Tumor and Endocrine Surgery, Academic Office One, 12631 East 17th Avenue, C311, Aurora, CO 80045, USA. [email protected]
Pages 477-490 | Published online: 10 Jan 2014

References

  • Yao JC, Eisner MP, Leary C et al. Population-based study of islet cell carcinoma. Ann. Surg. Oncol. 14(12), 3492–3500 (2007).
  • Yao JC, Lombard-Bohas C, Baudin E et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a Phase II trial. J. Clin. Oncol. 28(1), 69–76 (2010).
  • Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 135(5), 1469–1492 (2008).
  • Oberg K. Pancreatic endocrine tumors. Semin. Oncol. 37(6), 594–618 (2010).
  • Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol. Metab. Clin. North Am. 40(1), 1–18, vii (2011).
  • Grimelius L, Hultquist GT, Stenkvist B. Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material. Virchows Arch. A. Pathol. Anat. Histol. 365(4), 275–288 (1975).
  • Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig. Dis. Sci. 36(7), 933–942 (1991).
  • Burns WR, Edil BH. Neuroendocrine pancreatic tumors: guidelines for management and update. Curr. Treat. Options Oncol. 13(1), 24–34 (2012).
  • Batcher E, Madaj P, Gianoukakis AG. Pancreatic neuroendocrine tumors. Endocr. Res. 36(1), 35–43 (2011).
  • Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann. Oncol. 19(10), 1727–1733 (2008).
  • de Wilde RF, Edil BH, Hruban RH, Maitra A. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat. Rev. Gastroenterol. Hepatol. 9(4), 199–208 (2012).
  • Yao JC, Hassan M, Phan A et al. One hundred years after ‘carcinoid’: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26(18), 3063–3072 (2008).
  • Chen M, Van Ness M, Guo Y, Gregg J. Molecular pathology of pancreatic neuroendocrine tumors. J. Gastrointest. Oncol. 3(3), 182–188 (2012).
  • Zhou C, Zhang J, Zheng Y, Zhu Z. Pancreatic neuroendocrine tumors: a comprehensive review. Int. J. Cancer 131(5), 1013–1022 (2012).
  • Rindi G, Wiedenmann B. Neuroendocrine neoplasms of the gut and pancreas: new insights. Nat. Rev. Endocrinol. 8(1), 54–64 (2012).
  • Remes SM, Tuominen VJ, Helin H, Isola J, Arola J. Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices. Am. J. Surg. Pathol. 36(9), 1359–1363 (2012).
  • Strosberg JR, Cheema A, Weber JM et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann. Surg. 256(2), 321–325 (2012).
  • O’Grady HL, Conlon KC. Pancreatic neuroendocrine tumours. Eur. J. Surg. Oncol. 34(3), 324–332 (2008).
  • Li J, Luo G, Fu D et al. Preoperative diagnosis of nonfunctioning pancreatic neuroendocrine tumors. Med. Oncol. 28(4), 1027–1031 (2011).
  • Nissen NN, Kim AS, Yu R et al. Pancreatic neuroendocrine tumors: presentation, management, and outcomes. Am. Surg. 75(10), 1025–1029 (2009).
  • Milan SA, Yeo CJ. Neuroendocrine tumors of the pancreas. Curr. Opin. Oncol. 24(1), 46–55 (2012).
  • Kulke MH, Benson AB 3rd, Bergsland E et al.; National Comprehensive Cancer Networks. Neuroendocrine tumors. J. Natl Compr. Canc. Netw. 10(6), 724–764 (2012).
  • Anlauf M, Perren A, Klöppel G. Endocrine precursor lesions and microadenomas of the duodenum and pancreas with and without MEN1: criteria, molecular concepts and clinical significance. Pathobiology 74(5), 279–284 (2007).
  • Garbrecht N, Anlauf M, Schmitt A et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr. Relat. Cancer 15(1), 229–241 (2008).
  • Davies K, Conlon KC. Neuroendocrine tumors of the pancreas. Curr. Gastroenterol. Rep. 11(2), 119–127 (2009).
  • Abood GJ, Go A, Malhotra D, Shoup M. The surgical and systemic management of neuroendocrine tumors of the pancreas. Surg. Clin. North Am. 89(1), 249–266, x (2009).
  • Singh S, Law C. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Rev. Gastroenterol. Hepatol. 6(3), 313–334 (2012).
  • Vinik AI, Silva MP, Woltering EA et al. Biochemical testing for neuroendocrine tumors. Pancreas 38(8), 876–889 (2009).
  • Oberg K. Diagnostic work-up of gastroenteropancreatic neuroendocrine tumors. Clinics (Sao. Paulo) 67(Suppl. 1), 109–112 (2012).
  • Oberg K. Circulating biomarkers in gastroenteropancreatic neuroendocrine tumours. Endocr. Relat. Cancer 18(Suppl. 1), S17–S25 (2011).
  • Coakley FV, Hanley-Knutson K, Mongan J, Barajas R, Bucknor M, Qayyum A. Pancreatic imaging mimics: part 1, imaging mimics of pancreatic adenocarcinoma. AJR Am. J. Roentgenol. 199(2), 301–308 (2012).
  • Raman SP, Hruban RH, Cameron JL, Wolfgang CL, Fishman EK. Pancreatic imaging mimics: part 2, pancreatic neuroendocrine tumors and their mimics. AJR Am. J. Roentgenol. 199(2), 309–318 (2012).
  • Galvin A, Sutherland T, Little AF. Part 1: CT characterisation of pancreatic neoplasms: a pictorial essay. Insights Imaging 2(4), 379–388 (2011).
  • Pais SA, Al-Haddad M, Mohamadnejad M et al. EUS for pancreatic neuroendocrine tumors: a single-center, 11-year experience. Gastrointest. Endosc. 71(7), 1185–1193 (2010).
  • Ellison TA, Edil BH. The current management of pancreatic neuroendocrine tumors. Adv. Surg. 46, 283–296 (2012).
  • Joseph S, Wang YZ, Boudreaux JP et al. Neuroendocrine tumors: current recommendations for diagnosis and surgical management. Endocrinol. Metab. Clin. North Am. 40(1), 205–231, x (2011).
  • Ito T, Igarashi H, Jensen RT. Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances. J. Gastroenterol. 47(9), 941–960 (2012).
  • Frilling A, Akerström G, Falconi M et al. Neuroendocrine tumor disease: an evolving landscape. Endocr. Relat. Cancer 19(5), R163–R185 (2012).
  • Sundin A. Imaging of neuroendocrine tumors. Expert Opin. Med. Diagn. 6(5), 473–483 (2012).
  • Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plöckinger U. Multimodal management of neuroendocrine liver metastases. HPB (Oxford) 12(6), 361–379 (2010).
  • Frilling A, Sotiropoulos GC, Radtke A et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann. Surg. 252(5), 850–856 (2010).
  • Kim MK. Endoscopic ultrasound in gastroenteropancreatic neuroendocrine tumors. Gut Liver 6(4), 405–410 (2012).
  • Atiq M, Bhutani MS, Bektas M et al. EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience. Dig. Dis. Sci. 57(3), 791–800 (2012).
  • Lennon AM, Newman N, Makary MA et al. EUS-guided tattooing before laparoscopic distal pancreatic resection (with video). Gastrointest. Endosc. 72(5), 1089–1094 (2010).
  • Cauley CE, Pitt HA, Ziegler KM et al. Pancreatic enucleation: improved outcomes compared to resection. J. Gastrointest. Surg. 16(7), 1347–1353 (2012).
  • Pitt SC, Pitt HA, Baker MS et al. Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate? J. Gastrointest. Surg. 13(9), 1692–1698 (2009).
  • Bilimoria KY, Tomlinson JS, Merkow RP et al. Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J. Gastrointest. Surg. 11(11), 1460–1467; discussion 1467 (2007).
  • Casadei R, Ricci C, Rega D et al. Pancreatic endocrine tumors less than 4 cm in diameter: resect or enucleate? A single-center experience. Pancreas 39(6), 825–828 (2010).
  • Inchauste SM, Lanier BJ, Libutti SK et al. Rate of clinically significant postoperative pancreatic fistula in pancreatic neuroendocrine tumors. World J. Surg. 36(7), 1517–1526 (2012).
  • Cherif R, Gaujoux S, Couvelard A et al. Parenchyma-sparing resections for pancreatic neuroendocrine tumors. J. Gastrointest. Surg. 16(11), 2045–2055 (2012).
  • Falconi M, Zerbi A, Crippa S et al. Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors. Ann. Surg. Oncol. 17(6), 1621–1627 (2010).
  • Lavu H, Knuth JL, Baker MS et al. Middle segment pancreatectomy can be safely incorporated into a pancreatic surgeon’s clinical practice. HPB (Oxford) 10(6), 491–497 (2008).
  • Shoup M, Brennan MF, McWhite K, Leung DH, Klimstra D, Conlon KC. The value of splenic preservation with distal pancreatectomy. Arch. Surg. 137(2), 164–168 (2002).
  • Casadei R, Monari F, Buscemi S et al. Total pancreatectomy: indications, operative technique, and results: a single centre experience and review of literature. Updates Surg. 62(1), 41–46 (2010).
  • Imamura M. Recent standardization of treatment strategy for pancreatic neuroendocrine tumors. World J. Gastroenterol. 16(36), 4519–4525 (2010).
  • Heidt DG, Burant C, Simeone DM. Total pancreatectomy: indications, operative technique, and postoperative sequelae. J. Gastrointest. Surg. 11(2), 209–216 (2007).
  • Crippa S, Boninsegna L, Partelli S, Falconi M. Parenchyma-sparing resections for pancreatic neoplasms. J. Hepatobiliary Pancreat. Sci. 17(6), 782–787 (2010).
  • Kooby DA, Chu CK. Laparoscopic management of pancreatic malignancies. Surg. Clin. North Am. 90(2), 427–446 (2010).
  • Venkat R, Edil BH, Schulick RD, Lidor AO, Makary MA, Wolfgang CL. Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: a systematic review and meta-analysis. Ann. Surg. 255(6), 1048–1059 (2012).
  • Newman NA, Lennon AM, Edil BH et al. Preoperative endoscopic tattooing of pancreatic body and tail lesions decreases operative time for laparoscopic distal pancreatectomy. Surgery 148(2), 371–377 (2010).
  • Asbun HJ, Stauffer JA. Laparoscopic vs open pancreaticoduodenectomy: overall outcomes and severity of complications using the Accordion Severity Grading System. J. Am. Coll. Surg. 215(6), 810–819 (2012).
  • Lee LC, Grant CS, Salomao DR et al. Small, nonfunctioning, asymptomatic pancreatic neuroendocrine tumors (PNETs): role for nonoperative management. Surgery 152(6), 965–974 (2012).
  • Bettini R, Partelli S, Boninsegna L et al. Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery 150(1), 75–82 (2011).
  • Doherty GA, Bai A, Hanidziar D et al. CD73 is a phenotypic marker of effector memory Th17 cells in inflammatory bowel disease. Eur. J. Immunol. 42(11), 3062–3072 (2012).
  • Niina Y, Fujimori N, Nakamura T et al. The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1. Gut Liver 6(3), 287–294 (2012).
  • Gaujoux S, Gonen M, Tang L et al. Synchronous resection of primary and liver metastases for neuroendocrine tumors. Ann. Surg. Oncol. 19(13), 4270–4277 (2012).
  • Cusati D, Zhang L, Harmsen WS et al. Metastatic nonfunctioning pancreatic neuroendocrine carcinoma to liver: surgical treatment and outcomes. J. Am. Coll. Surg. 215(1), 117–124; discussion 124 (2012).
  • Kulke MH, Anthony LB, Bushnell DL et al.; North American Neuroendocrine Tumor Society (NANETS). NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 39(6), 735–752 (2010).
  • Franko J, Feng W, Yip L, Genovese E, Moser AJ. Non-functional neuroendocrine carcinoma of the pancreas: incidence, tumor biology, and outcomes in 2,158 patients. J. Gastrointest. Surg. 14(3), 541–548 (2010).
  • Watzka FM, Laumen C, Fottner C et al. Resection strategies for neuroendocrine pancreatic neoplasms. Langenbecks. Arch. Surg. 398(3), 431–440 (2013).
  • De Jong MC, Farnell MB, Sclabas G et al. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis. Ann. Surg. 252(1), 142–148 (2010).
  • Kimura W, Tezuka K, Hirai I. Surgical management of pancreatic neuroendocrine tumors. Surg. Today 41(10), 1332–1343 (2011).
  • Chan G, Kocha W, Reid R, Taqi A, Wall W, Quan D. Liver transplantation for symptomatic liver metastases of neuroendocrine tumours. Curr. Oncol. 19(4), 217–221 (2012).
  • Alistar A, Sung M, Kim M, Holcombe RF. Clinical pathways for pancreatic neuroendocrine tumors. J. Gastrointest. Cancer 43(4), 532–540 (2012).
  • Reddy SK, Clary BM. Neuroendocrine liver metastases. Surg. Clin. North Am. 90(4), 853–861 (2010).
  • Reidy-Lagunes D, Thornton R. Pancreatic neuroendocrine and carcinoid tumors: what’s new, what’s old, and what’s different? Curr. Oncol. Rep. 14(3), 249–256 (2012).
  • Eriksson B. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies? Curr. Opin. Oncol. 22(4), 381–386 (2010).
  • Rinke A, Müller HH, Schade-Brittinger C et al.; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 27(28), 4656–4663 (2009).
  • Kwekkeboom DJ, de Herder WW, Kam BL et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol. 26(13), 2124–2130 (2008).
  • Imhof A, Brunner P, Marincek N et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J. Clin. Oncol. 29(17), 2416–2423 (2011).
  • Sowa-Staszczak A, Pach D, Chrzan R et al. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs). Eur. J. Nucl. Med. Mol. Imaging 38(9), 1669–1674 (2011).
  • Delaunoit T, Neczyporenko F, Rubin J, Erlichman C, Hobday TJ. Medical management of pancreatic neuroendocrine tumors. Am. J. Gastroenterol. 103(2), 475–483; quiz 484 (2008).
  • Yalcin S. Advances in the systemic treatment of pancreatic neuroendocrine tumors. Cancer Treat. Rev. 37(2), 127–132 (2011).
  • Oberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-entero-pancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann. Oncol. 23(Suppl. 7), vii 124–130 (2012).
  • Eriksson B, Annibale B, Bajetta E et al.; Mallorca Consensus Conference participants; European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 90(2), 214–219 (2009).
  • Oberstein PE, Saif MW. Update on novel therapies for pancreatic neuroendocrine tumors. JOP 13(4), 372–375 (2012).
  • Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin–doxorubicin, streptozocin–fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N. Engl. J. Med. 326(8), 519–523 (1992).
  • Kouvaraki MA, Ajani JA, Hoff P et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J. Clin. Oncol. 22(23), 4762–4771 (2004).
  • Strosberg JR, Fine RL, Choi J et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117(2), 268–275 (2011).
  • Jiao Y, Shi C, Edil BH et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331(6021), 1199–1203 (2011).
  • Chan JA, Kulke MH. New treatment options for patients with advanced neuroendocrine tumors. Curr. Treat. Options Oncol. 12(2), 136–148 (2011).
  • Yao JC, Phan AT, Chang DZ et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a Phase II study. J. Clin. Oncol. 26(26), 4311–4318 (2008).
  • Yao JC, Shah MH, Ito T et al.; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med. 364(6), 514–523 (2011).
  • Raymond E, Dahan L, Raoul JL et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364(6), 501–513 (2011).
  • Kulke MH, Lenz HJ, Meropol NJ et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 26(20), 3403–3410 (2008).
  • Chan JA, Mayer RJ, Jackson N, Malinowski P, Regan E, Kulke MH. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors. Cancer Chemother. Pharmacol. 71(5), 1241–1246 (2013).
  • Phan AT, Oberg K, Choi J et al.; North American Neuroendocrine Tumor Society (NANETS). NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas 39(6), 784–798 (2010).
  • Reidy-Lagunes DL, Vakiani E, Segal MF et al. A Phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors. Cancer 118(19), 4795–4800 (2012).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.